First Time Loading...

Shandong Xinhua Pharmaceutical Co Ltd
SZSE:000756

Watchlist Manager
Shandong Xinhua Pharmaceutical Co Ltd Logo
Shandong Xinhua Pharmaceutical Co Ltd
SZSE:000756
Watchlist
Price: 15.17 CNY 0.07% Market Closed
Updated: Jun 10, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Balance Sheet

8.5B
+2%
Assets
Growth Rates:
1 Year
+6%
3 Years
-
5 Years
-
7 Years
-
10 Years
-
3.7B
-0.8%
Liabilities
Growth Rates:
1 Year
+1%
3 Years
-
5 Years
-
7 Years
-
10 Years
-
4.8B
+5%
Equity
Growth Rates:
1 Year
+10%
3 Years
-
5 Years
-
7 Years
-
10 Years
-

Balance Sheet Decomposition
Shandong Xinhua Pharmaceutical Co Ltd

8.5B
Assets
3.7B
Liabilities
8.5B
Assets
3.7B
Liabilities
Current Assets 3.5B
Cash & Short-Term Investments 922.1m
Receivables 1.3B
Other Current Assets 1.3B
Non-Current Assets 5B
Long-Term Investments 276.7m
PP&E 4.1B
Intangibles 490.2m
Other Non-Current Assets 150.4m
Current Liabilities 2.4B
Accounts Payable 643.2m
Accrued Liabilities 91.3m
Short-Term Debt 760.4m
Other Current Liabilities 946.2m
Non-Current Liabilities 1.3B
Long-Term Debt 798.4m
Other Non-Current Liabilities 463.6m

Balance Sheet
Shandong Xinhua Pharmaceutical Co Ltd

Rotate your device to view
Balance Sheet
Currency: CNY
Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022 Dec-2023
Assets
Cash & Cash Equivalents
329
476
561
731
687
579
723
596
1 011
782
Cash
0
0
0
0
0
0
0
0
1 011
782
Cash Equivalents
329
476
561
731
687
579
723
596
0
0
Total Receivables
482
598
522
524
557
534
607
920
1 032
1 017
Accounts Receivables
312
314
343
313
343
309
380
659
763
701
Other Receivables
170
284
179
211
213
225
227
261
269
317
Inventory
589
547
560
713
969
1 130
1 124
1 028
1 212
1 313
Other Current Assets
63
31
68
42
169
185
233
211
202
202
Total Current Assets
1 462
1 652
1 711
2 010
2 381
2 428
2 687
2 754
3 457
3 314
PP&E Net
2 154
2 241
2 438
2 588
2 945
3 201
3 539
3 766
4 000
4 061
PP&E Gross
2 154
2 241
2 438
2 588
2 945
3 201
3 539
3 766
4 000
4 061
Accumulated Depreciation
1 212
1 379
1 587
1 761
1 966
2 252
2 538
2 913
3 280
3 667
Intangible Assets
313
295
283
324
337
412
449
467
474
495
Long-Term Investments
290
279
265
332
260
369
367
306
288
275
Other Long-Term Assets
26
26
26
21
30
26
51
40
46
141
Total Assets
4 245
N/A
4 492
+6%
4 723
+5%
5 274
+12%
5 953
+13%
6 436
+8%
7 093
+10%
7 332
+3%
8 265
+13%
8 286
+0%
Liabilities
Accounts Payable
361
381
433
530
465
434
453
661
599
666
Accrued Liabilities
43
46
82
80
95
95
133
109
193
155
Short-Term Debt
552
746
1 164
360
667
904
490
710
621
800
Current Portion of Long-Term Debt
409
586
345
90
607
349
358
391
317
273
Other Current Liabilities
236
193
247
431
527
704
946
631
1 428
591
Total Current Liabilities
1 601
1 951
2 271
1 491
2 361
2 486
2 381
2 502
3 158
2 486
Long-Term Debt
636
430
165
979
590
641
1 087
953
548
801
Deferred Income Tax
15
10
1
17
31
54
69
66
66
99
Minority Interest
91
100
91
99
120
142
168
183
223
223
Other Liabilities
81
117
207
207
156
145
165
160
142
124
Total Liabilities
2 425
N/A
2 608
+8%
2 734
+5%
2 794
+2%
3 257
+17%
3 467
+6%
3 869
+12%
3 864
0%
4 139
+7%
3 733
-10%
Equity
Common Stock
457
457
457
478
622
622
622
627
670
675
Retained Earnings
692
766
879
1 074
1 293
1 531
1 783
2 036
2 346
2 710
Additional Paid In Capital
507
513
513
729
638
634
645
678
998
1 055
Unrealized Security Profit/Loss
0
0
0
0
0
0
0
0
111
112
Other Equity
165
148
139
199
143
182
174
126
1
2
Total Equity
1 821
N/A
1 884
+3%
1 988
+6%
2 480
+25%
2 696
+9%
2 969
+10%
3 224
+9%
3 468
+8%
4 126
+19%
4 553
+10%
Total Liabilities & Equity
4 245
N/A
4 492
+6%
4 723
+5%
5 274
+12%
5 953
+13%
6 436
+8%
7 093
+10%
7 332
+3%
8 265
+13%
8 286
+0%
Shares Outstanding
Common Shares Outstanding
595
595
595
622
622
622
622
627
670
675

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 146,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.